JP2023523155A - 慢性疼痛治療のためのカンナビジオール及び／又はテトラヒドロカンナビノールを含有する経皮製剤及び／又は局所製剤 - Google Patents

慢性疼痛治療のためのカンナビジオール及び／又はテトラヒドロカンナビノールを含有する経皮製剤及び／又は局所製剤 Download PDF

Info

Publication number
JP2023523155A
JP2023523155A JP2022560857A JP2022560857A JP2023523155A JP 2023523155 A JP2023523155 A JP 2023523155A JP 2022560857 A JP2022560857 A JP 2022560857A JP 2022560857 A JP2022560857 A JP 2022560857A JP 2023523155 A JP2023523155 A JP 2023523155A
Authority
JP
Japan
Prior art keywords
once
days
transdermal
pain
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523155A5 (enExample
Inventor
プラコヤニス，フォショス，エム．
ラザー，タマンナ
Original Assignee
パイク セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パイク セラピューティクス，インコーポレイテッド filed Critical パイク セラピューティクス，インコーポレイテッド
Publication of JP2023523155A publication Critical patent/JP2023523155A/ja
Publication of JP2023523155A5 publication Critical patent/JP2023523155A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022560857A 2020-04-20 2021-04-20 慢性疼痛治療のためのカンナビジオール及び／又はテトラヒドロカンナビノールを含有する経皮製剤及び／又は局所製剤 Pending JP2023523155A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063012428P 2020-04-20 2020-04-20
US63/012,428 2020-04-20
PCT/IB2021/000261 WO2021214545A1 (en) 2020-04-20 2021-04-20 Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain

Publications (2)

Publication Number Publication Date
JP2023523155A true JP2023523155A (ja) 2023-06-02
JP2023523155A5 JP2023523155A5 (enExample) 2024-05-23

Family

ID=78270322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560857A Pending JP2023523155A (ja) 2020-04-20 2021-04-20 慢性疼痛治療のためのカンナビジオール及び／又はテトラヒドロカンナビノールを含有する経皮製剤及び／又は局所製剤

Country Status (8)

Country Link
US (2) US20210346310A1 (enExample)
EP (1) EP4110325A4 (enExample)
JP (1) JP2023523155A (enExample)
CN (1) CN115916184A (enExample)
AU (1) AU2021259495A1 (enExample)
CA (1) CA3178878A1 (enExample)
MX (1) MX2022012415A (enExample)
WO (1) WO2021214545A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
MX2023006561A (es) * 2020-12-03 2023-07-06 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
AU2022260813A1 (en) * 2021-04-22 2023-10-26 Pike Therapeutics Inc. Transdermal pharmaceutical formulations for the treatment of chronic pain
EP4366728A4 (en) * 2021-07-08 2025-05-14 Innocan Pharma Ltd. COMPOSITIONS FOR THE TREATMENT OF DIABETIC SYMPTOMS
US20230059204A1 (en) * 2021-08-03 2023-02-23 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
US20250222012A1 (en) * 2021-11-02 2025-07-10 Schedule 1 Therapeutics, Inc. Use of cannabinoid compositions for treating pain associated with small fiber neuropathy
US20240024253A1 (en) * 2022-07-21 2024-01-25 Pike Therapeutics Inc. Continuous Drug Delivery Systems and Methods
US11826342B1 (en) * 2022-09-27 2023-11-28 Saaransh Mahna Cannabidiol formulation for alleviating pain and a method of manufacturing
CN118045221B (zh) * 2024-02-04 2024-07-19 广东云曌医疗科技有限公司 一种水凝胶敷料及其制备方法和应用
WO2026018119A1 (en) * 2024-07-16 2026-01-22 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202891A1 (en) * 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
JP2013503206A (ja) * 2009-08-31 2013-01-31 オールトランツ インコーポレイティド マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
US20150126595A1 (en) * 2014-12-04 2015-05-07 Mary's Medicinals LLC Transdermal cannabinoid formulations
US20170000744A1 (en) * 2015-03-10 2017-01-05 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
JP2018507262A (ja) * 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
US20190358197A1 (en) * 2017-02-20 2019-11-28 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
JP2019537628A (ja) * 2016-11-02 2019-12-26 ティクン オラム リミテッドＴｉｋｕｎ Ｏｌａｍ ＬＴＤ 併用療法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9095563B2 (en) * 2013-09-26 2015-08-04 Ronald D. Sekura Topical treatments incorporating Cannabis sp. derived botanical drug product
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
CA2976004C (en) * 2015-02-05 2020-06-02 Colorado Can Llc Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
MX2018004034A (es) * 2015-09-30 2018-12-19 Edward Hoag George Formulaciones topicas de analgesicos para alivio del dolor fabricacion y uso de los mismos.
FR3064334B1 (fr) * 2017-03-24 2021-05-14 Dcns Energies Presse-etoupe de traversee etanche d'un orifice d'une cloison
US12357604B2 (en) * 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
CA3076929A1 (en) * 2017-09-25 2019-03-28 Canopy Health Innovations Compositions comprising cannabidiol, tetrahydrocannabinol, terpenes, and flavonoids and use thereof in the treatment of insomnia
IL292126B2 (en) * 2018-01-12 2025-04-01 Nutrae Llc Cannabinoid formulations are formulated for oral administration
US20200138772A1 (en) * 2018-07-09 2020-05-07 Volker Berl Stabilized formulations of cannabinoid compositions
US20210015740A1 (en) * 2019-03-04 2021-01-21 Michael Harvey Greenspan Topical cannabinoid compositions, delivery systems, and uses for pain relief
EP3969054A4 (en) * 2019-05-16 2023-09-06 Aegis Therapeutics, LLC COMPOSITIONS CONTAINING OIL-SOLUBLE DRUGS AND METHODS OF USING SUCH COMPOSITIONS

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202891A1 (en) * 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
JP2013503206A (ja) * 2009-08-31 2013-01-31 オールトランツ インコーポレイティド マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
US20150126595A1 (en) * 2014-12-04 2015-05-07 Mary's Medicinals LLC Transdermal cannabinoid formulations
JP2018507262A (ja) * 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
US20170000744A1 (en) * 2015-03-10 2017-01-05 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
JP2019537628A (ja) * 2016-11-02 2019-12-26 ティクン オラム リミテッドＴｉｋｕｎ Ｏｌａｍ ＬＴＤ 併用療法
US20190358197A1 (en) * 2017-02-20 2019-11-28 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia

Also Published As

Publication number Publication date
WO2021214545A1 (en) 2021-10-28
AU2021259495A1 (en) 2022-10-27
EP4110325A1 (en) 2023-01-04
CN115916184A (zh) 2023-04-04
EP4110325A4 (en) 2024-07-03
CA3178878A1 (en) 2021-10-28
US20210346310A1 (en) 2021-11-11
MX2022012415A (es) 2023-02-09
US20250248948A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
CN115916184A (zh) 包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂
JP2023537840A (ja) ナビロンを単独及びカンナビノイドと併用する経皮製剤
JP7670700B2 (ja) 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
CN116075296A (zh) 用于治疗多发性硬化症的透皮药物制剂
CN114555068A (zh) 大麻二酚的透皮给药
UA125040C2 (uk) Фенітоїн для місцевого застосування для використання при лікуванні периферичного нейропатичного болю
US20240261235A1 (en) Pharmaceutical Composition And Method For Treating Seizure Disorders
JP2023520845A (ja) ヒドロキシクロロキン及び／又はクロロキンを含む経口送達システム
JP2024514362A (ja) 慢性疼痛の処置のための経皮医薬製剤
JP2024514843A (ja) 発作性疾患を治療するための医薬組成物及び方法
JPWO2004112837A1 (ja) 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン−１α生成抑制剤
KR20070059079A (ko) 경피 페로스피론 투여용 의약적 조성물
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders
JP2024513961A (ja) カンナビジオールの経皮送達

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202